News from mallinckrodt pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 04, 2020, 06:45 ET Mallinckrodt Announces Positive Findings in INOmax® (Nitric Oxide) Gas, for Inhalation Phase 4 Observational Registry in Neonates with Pulmonary Hypertension; Ends Trial Early

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that its observational registry comparing the safety and...


Apr 30, 2020, 08:04 ET Mallinckrodt Supports Investigator-Initiated Study at Massachusetts General Hospital to Assess Effectiveness of Inhaled Nitric Oxide in Patients with Severe Acute Respiratory Distress Syndrome Due to COVID-19

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it is supporting an investigator-initiated clinical study at...


Apr 22, 2020, 06:45 ET Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Filing Acceptance of New Drug Application for Terlipressin for Treatment of Hepatorenal Syndrome Type 1 (HRS-1)

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for...


Apr 15, 2020, 06:45 ET Mallinckrodt Announces Publication of Data on Acthar® Gel (Repository Corticotropin Injection) from its Randomized, Double-Blind, Placebo-Controlled Phase 4 Study in Rheumatoid Arthritis (RA) in Rheumatology and Therapy

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced the publication of findings from its randomized,...


Apr 01, 2020, 06:45 ET Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19 Infection and Associated Lung Complications

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Novoteris, LLC, a clinical stage medical device and pharmaceutical developer...


Mar 17, 2020, 06:45 ET Mallinckrodt Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced the completion of its rolling submission of a New Drug Application...


Mar 12, 2020, 06:45 ET Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide to Treat COVID-19 Associated Lung Complications, Engages with Scientific, Governmental and Regulatory Agencies

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today commented that it is currently evaluating the limited published evidence...


Mar 05, 2020, 06:45 ET Data on Acthar® Gel (Repository Corticotropin Injection) Therapy in Immunoglobulin A Nephropathy (IgAN) Published in Kidney International Reports

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced publication of findings from a prospective, open-label pilot study...


Mar 04, 2020, 06:45 ET Mallinckrodt Announces Publication of New Data on Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis, Systemic Lupus Erythematosus and Dermatomyositis/Polymyositis Published in Open Access Rheumatology: Research and Reviews

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced findings from a retrospective medical record analysis to assess...


Mar 02, 2020, 06:45 ET Mallinckrodt Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it initiated the rolling submission of a New Drug Application (NDA) ...


Feb 27, 2020, 06:45 ET Mallinckrodt to Present New Data from two Studies on Acthar® Gel (Repository Corticotropin Injection) Therapy in Multiple Sclerosis (MS) Relapse at Fifth Annual ACTRIMS Forum 2020

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will present new data from two studies of Acthar® Gel...


Oct 31, 2019, 16:35 ET Mallinckrodt Announces UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in Adults

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that UVADEX® (methoxsalen) has received regulatory approval in...


Sep 20, 2019, 06:45 ET Mallinckrodt to Present at Cantor Global Healthcare Conference

Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present at the Cantor Global Healthcare Conference at the...


Aug 21, 2019, 06:55 ET Mallinckrodt to Present at Morgan Stanley 17th Annual Global Healthcare Conference

Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, Sept. 10, 2019, at the Morgan Stanley 17th...


Aug 12, 2019, 06:45 ET First Patient Enrolled in Mallinckrodt's Phase 2a Study of Investigational Drug MNK-6106 in Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE)

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 2a study...


Aug 02, 2019, 06:55 ET Mallinckrodt to Present at Wells Fargo Securities 2019 Healthcare Conference

Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Thursday, Sept. 5, 2019, at the Wells Fargo Securities...


Jun 11, 2019, 06:55 ET Mallinckrodt to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference

Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 25, 2019, at the BMO Capital Markets 2019 ...


May 31, 2019, 06:55 ET Mallinckrodt to Present at Raymond James Life Sciences and Medtech Conference

Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Wednesday, June 19, 2019, at the Raymond James Life...


Apr 18, 2019, 06:45 ET Mallinckrodt Reports Top-Line Results from Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced top-line results from its company-sponsored,...


Apr 11, 2019, 06:45 ET Mallinckrodt and Washington University St. Louis Select First Collaborative Research Endeavor

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has selected the first collaborative research...


Mar 15, 2019, 06:55 ET Mallinckrodt's Hobart, N.Y. and St. Louis, Mo. Sites Recognized as 2019 Manufacturing Leadership Award Winners

Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading specialty pharmaceutical company, announced today that sites owned and operated by subsidiaries...


Feb 25, 2019, 06:55 ET Mallinckrodt Announces Extracorporeal Photopheresis Research Collaboration Agreement With Transimmune AG

Mallinckrodt Pharmaceuticals (NYSE:MNK), a leading global specialty pharmaceutical company, today announced it has entered into a research...


Feb 20, 2019, 06:55 ET Mallinckrodt Announces Interim Analysis Results for Therakos® Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease

Mallinckrodt Pharmaceuticals (NYSE:MNK), a leading global specialty pharmaceutical company, today announced interim analysis results of its...


Feb 12, 2019, 06:55 ET Mallinckrodt To Present At Barclays Global Healthcare Conference

Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Tuesday, March 12, 2019, at Barclays...


Dec 17, 2018, 06:30 ET Mallinckrodt To Present At 37th Annual J.P. Morgan Healthcare Conference

Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Monday, Jan. 7, 2019, at the 37th Annual ...